


RECEIVED

NOV 05 2003

TECH CENTER 1600/2900

Certificate of Mailing

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to Mail Stop: Non-Fee Amendment, Commissioner For Patents, P O Box 1450, Alexandria, Virginia 22313-1450, on this 29th day of October 2003.

  
Bonnie Acosta

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



<p><b>In re the Application of:</b> <b>M. McTigue et al.</b></p> <p><b>Serial No.:</b> 09/939,833</p> <p><b>Confirmation No.:</b> 3848</p> <p><b>Filed:</b> August 28, 2001</p> <p><b>For:</b> MODIFICATIONS OF VEGF RECEPTOR-2 PROTEIN AND METHOD OF USE</p>	<p><b>Group Art Unit:</b> 1637</p> <p><b>Examiner:</b> K. Young</p> <p><b>Attorney Docket No.:</b> 0069-02 (formerly 0125-0016D1)</p>
---	---

Honorable Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST TO OPEN NEW DISK FILE**

Sir:

In response to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures references in the Office action mailed August 12, 2003, Applicants request that a new disk file be opened for the above-captioned application. The Sequence Listing disk submitted on February 28, 2000, in the parent, Application No. 09/390,326 (filed September 9, 1999, now U.S. Patent No. 6,316,603), contains the identical sequence information as that in the present application. Please enter the new disk file as a substitute computer readable copy of the sequence listing.


Applicants submit herewith a substitute paper copy of the sequence listing for the present application, and hereby request that the attached substitute sequence listing be entered into the file of the above-identified application, replacing the previously submitted sequence listing.

The paper copy of the sequence listing and the computer readable copy are the same, and do not introduce new matter.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: October 29, 2003

  
\_\_\_\_\_  
Stephen D. Prodnuk  
Attorney For Applicants  
Registration No. 43,020

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 622-3087  
Fax: (858) 678-8233